ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB323

Post-COVID-19 Vaccine Activation of IgA Vasculitis

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: Mechanisms, including Podocyte Biology

Authors

  • Fardi, Yasameen, University Hospitals, Cleveland, Ohio, United States
  • Desai, Niraj, University Hospitals, Cleveland, Ohio, United States
  • Kapp, Meghan, University Hospitals, Cleveland, Ohio, United States
Background

A 69 year old female with hypertension and longstanding microscopic hematuria received Pfizer BioTech SARS-COV-2 vaccine. Three weeks post vaccination, the patient developed diffuse abdominal pain and a palpable, right lower extremity purpuric rash.

Methods

Skin biopsy was consistent with leukocytoclastic vasculitis. Serologic workup was negative. Kidney function was normal, but there was newly identified proteinuria on urinalysis and redemonstrated microscopic hematuria. Urine protein/creatinine ratio was 1.6 g/g. Histopathologic examination revealed mild mesangial hypercellularity and immunofluorescense showed IgA dominant mesangial staining (Fig 1). Electron microscopy showed mesangial deposits. The constellation of symptoms and biopsy findings were consistent with an IgA Vasculitis, suspected to be associated with recent SARS-CoV-2 vaccination. The patient was treated with ace inhibition and sglt2 inhibition, resulting in reduction in proteinuria to less than 200 mg/g and preservation of renal function. The rash resolved with no additional intervention.

Results

Development of abdominal pain, purpuric rash and sub-nephrotic proteinuria after vaccination raises possibility that SARS-CoV-2 vaccination may have triggered a de-novo IgA vasculitis or, given the longstanding, unexplained microscopic hematuria, may have exacerbated a pre-existing, otherwise quiescent IgA nephropathy.

Conclusion

In susceptible individuals, an aberrant immune response triggered by vaccination may result in production and deposition of galactose deficient-IgA1 in glomeruli, activating an inflammatory cascade leading to glomerular injury and possibly a systemic vasculitis. However, despite the temporal association, both a causative link between, and pathogenic mechanisms underlying SARS-CoV-2 vaccination and IgA vasculitis remain incompletely elucidated.

Figure 1